IMPACT OF HEMODIALYSIS ON FOLATE METABOLISM, HYPERHOMOCYSTEINEMIA, AND ANEMIA SEVERITY IN PATIENTS WITH END-STAGE CHRONIC KIDNEY DISEASE
Keywords:
A cross-sectional study was conducted among patients diagnosed with stage 5 Chronic kidney disease undergoing regular hemodialysis (three sessions per week), The following laboratory parameters were evaluated, Serum folate concentration, Serum folate concentrationPlasma homocysteine levels, Hemoglobin, mean corpuscular volume (MCV), and erythrocyte indices, Serum creatinine and estimated glomerular filtration rate (eGFR), C-reactive protein (CRP) as a marker of inflammationAbstract
Chronic kidney disease (CKD) is a major global health problem associated with high morbidity and mortality. In its terminal stage (stage 5 CKD), patients require renal replacement therapy, most commonly maintenance hemodialysis. Anemia is one of the most prevalent complications in end-stage renal disease (ESRD) and is traditionally attributed to erythropoietin deficiency. However, growing evidence suggests that disturbances in micronutrient metabolism, particularly folate and other B vitamins, play an important contributory role. Folate is essential for DNA synthesis, erythropoiesis, and homocysteine remethylation. In Chronic kidney disease patients, reduced renal clearance, chronic inflammation, oxidative stress, and dialysis-related nutrient losses may alter folate homeostasis. Hyperhomocysteinemia, frequently observed in ESRD, is strongly associated with endothelial dysfunction and increased cardiovascular risk. Therefore, investigating folate metabolism in patients undergoing long-term hemodialysis is of significant clinical importance. To assess the impact of maintenance hemodialysis on serum folate levels and to evaluate their association with hyperhomocysteinemia and anemia severity in patients with end-stage Chronic kidney disease
